XBIT News and Press, XBiotech Inc. From 03/01/19

Rapid and significant reduction in skin lesions, 66% (p<0.001) and 76% (p<0.001) mean reduction in EASI score in 4 and 7 weeks, respectively.   Rapid and significant resolution of worst itch and pain, 57% (p<0.001) and 61% (p<0.001) mean reduction within 4 weeks, respecti...

Noteworthy events during the week of February 24 - March 2 for healthcare investors. More news on: uniQure N.V., Bausch Health Companies Inc., CytomX Therapeutics, Healthcare stocks news, , Read more ...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

CORAL GABLES, FL / ACCESSWIRE / February 6, 2019 / The biotech stock market has always been a sector replete with innovation, and conversation surrounding companies looking into nuanced approaches to designing effective treatment options for patients suffering a wide array of diseases. Acc...

Bermekimab Rapidly Treats Atopic Dermatitis While Reducing Itch and Pain AUSTIN, Texas, Jan. 29, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that findings from its open label, multicenter study using bermekimab to treat patients with moderate to severe atopic dermatitis...

AUSTIN, Texas, Jan. 28, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb, M.D., Ph.D., will be giving the presentation “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the ...

PI   +39%  on Q2 earnings . More news on: Impinj, Inc., Geron Corporation, GNC Holdings, Inc., Stocks on the move, , Read more ...

Thinly traded micro cap XBiotech (NASDAQ: XBIT ) is up  28%  premarket on light volume in apparent response to preliminary data from an open-label pilot study evaluating IL-1 alpha inhibitor bermekimab in patients with atopic dermatitis (AD). More news on: Xbiotech, Healthcare ...

AUSTIN, Texas, Sept. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis (AD).  In the first phase of the study, 9 patients received a low dose (200mg/weekly) over a short course o...

Gainers:  NMRD +47% . XBIT +27% . CIFS +23% . ARCI +18% . GLPG +17% . SLDB +17% . VVUS +15% . MHLD +15% . CDXC +14% . BHC +13% . More news on: Nemaura Medical, Inc., Xbiotech, China Internet Nationwide Financial Services Inc., Stocks on the move, , ...